Business Context and Reporting Period
This Form 8-K filing by Avalo Therapeutics, Inc. (AVTX) reports a corporate action effective July 7, 2022. The Company, incorporated in Delaware and listed on the Nasdaq Capital Market, implemented a reverse stock split to maintain compliance with Nasdaq listing criteria.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure adjustments.
Material Changes
- Reverse Stock Split: A 1-for-12 reverse stock split was effected at 5:00 p.m. on July 7, 2022.
- Share Count Reduction: Outstanding shares decreased from approximately 112,868,677 to approximately 9,405,724.
- Authorized Shares: The number of authorized shares was not reduced, increasing the pool of shares available for future issuance.
- Equity Adjustments: Exercise prices and share counts for outstanding options and warrants were adjusted proportionately. The equity incentive plan's authorized share count was also reduced proportionately.
- Fractional Shares: No fractional shares were issued; holders entitled to fractions received one whole share.
Outlook, Risks, and Management Commentary
Management stated the primary purpose of the reverse stock split was to enable the Company to meet the continued listing criteria for the Nasdaq Capital Market. The filing notes that stockholder percentage ownership and proportional voting power remain unchanged, except for minor adjustments due to rounding. The transfer agent, American Stock Transfer & Trust Company, will handle the exchange automatically in book-entry form.
Key Facts for Investor Verification
- Verify the adjusted share count of approximately 9.4 million shares in brokerage accounts.
- Confirm the adjusted exercise prices and share quantities for any held options or warrants.
- Check current Nasdaq listing status to ensure compliance requirements are met post-split.
- Review the press release (Exhibit 99.1) for any additional strategic context not detailed in the 8-K.